2022 News

• 11.29.2022
  Press Release

  Notice of Personnel Changes

• 11.21.2022
  Press Release

  Santen launches the dry-eye treatment DIQUAS® LX Ophthalmic Solution 3% in Japan - Improved formulation to reduce administration frequency to three-times daily, thus easing patients' burden -

• 10.26.2022
  Press Release

  Santen Strengthens Global Product Supply Base with Completion of Third Building on Site of Shiga Product Supply Center

• 10.14.2022
  Press Release

  Santen Publishes its Annual Integrated Report "Santen Report 2022"

• 10.06.2022
  Press Release

  Santen filing accepted by European Medicines Agency (EMA) for review of application for marketing authorization of the use of STN1013001 cationic emulsion of latanoprost 50?g/mL in glaucoma

• 09.26.2022
  Press Release

  Ophthalmic VEGF inhibitor Eylea® Solution for Intravitreal Injection 40 mg/mL obtains approval for ROP as sixth indication

• 09.26.2022
  Press Release

  Santen and UBE Received FDA Approval for OMLONTI® (Omidenepag Isopropyl Ophthalmic Solution) 0.002% for the Reduction of Elevated Intraocular Pressure in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension

• 09.12.2022
  Press Release

  Notice of Personnel Change

• 06.29.2022
  Press Release

  Santen Announces Endorsement of Task Force on Climate-Related Financial Disclosures (TCFD)

• 06.20.2022
  Press Release

  Santen receives manufacturing and marketing approval for the dry-eye treatment DIQUAS LX Ophthalmic Solution 3% in Japan - Improved formulation to reduce administration frequency to three-times daily, thus easing patients' burden -

• 06.10.2022
  Press Release

  Santen and UBE announces U.S. Food and Drug Administration accepts resubmission of NDA for STN1011700 / DE-117 (omidenepag isopropyl) for treating glaucoma and ocular hypertension

• 05.31.2022
  Press Release

  Santen and ActualEyes start registering patients to participate in Phase II clinical trial (Phase IIa / PoC study, PHANTOM study) for Fuchs endothelial corneal dystrophy

• 05.10.2022
  Press Release

  Santen Received the Approval of Verkazia (Ciclosporin Eye Drops (III)), Providing New Solutions for Severe Vernal Keratoconjunctivitis in China

• 05.02.2022
  Press Release

  Santen's Verkazia (Cyclosporine Ophthalmic Emulsion) 0.1% Now Available for the Treatment of Vernal Keratoconjunctivitis in Children and Adults in the United States

• 02.28.2022
  Press Release

  Santen Receives Marketing Approval in Japan for "PRESERFLO MicroShunt Glaucoma Drainage System Core Kit" to Treat Glaucoma

• 02.22.2022
  Press Release

  Reinventing of Our Leadership Team to Shape the Future of Santen

• 02.10.2022
  Press Release

  Santen certified as Digital Transformation Business Operator by Ministry of Economy, Trade and Industry

News Archive